Veritable’s Rocket Pharmaceuticals RCKT Stock Holding History

Veritable’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,211	Closed	-$168K	–	875
2022 Q2	$168K	Buy	+12,211	New	+$146K	﹤0.01%	842

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Veritable's RCKT Position: Q3 2022 in Review

Veritable sold out of Rocket Pharmaceuticals (RCKT) in Q3 2022, closing a stake of 12,211 shares — an estimated $168K sold.

Veritable first reported a position in RCKT in Q2 2022 and held it in 1 quarter. The position peaked at $168K in Q2 2022. 164 funds tracked by Wall St. Rank hold RCKT as of Q3 2022.

Veritable reported no remaining Rocket Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Veritable sold 12,211 Rocket Pharmaceuticals shares in Q3 2022, an estimated $168K.
Veritable first reported a position in Rocket Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Veritable's Rocket Pharmaceuticals position peaked at $168K in Q2 2022.
164 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.